Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,789 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Sham Treatment Clear all

Conditions: Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions: Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Cancer
Interventions: Psilocybin 25 mgs, Niacin 100mg, Psychotherapy; Drug · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: Cognitive Dysfunction, Schizophrenia
Interventions: KYN-5356, placebo; Drug
Lead sponsor: Kynexis B.V.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Vestibulocochlear Nerve Diseases, Vestibular Disorder, Bilateral Vestibular Loss
Interventions: Vestibular Balance Therapy, Sham Intervention; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 4 Years to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Burnout, Professional
Interventions: One-on-one professional coaching, Small-group professional coaching; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%, SBI-100 Ophthalmic Emulsion, Placebo; Drug
Lead sponsor: Skye Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Glendale, California • Newport Beach, California • Cranberry Township, Pennsylvania

Conditions: Obesity
Interventions: Milk Thistle (MT), Lactobacillus Gasseri (LAC), Exercise (EX), Control (CON); Dietary Supplement · Behavioral
Lead sponsor: Kyle Flack; Other
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Alcohol Dependence, Insomnia
Interventions: Placebo dispensed to subject., Gabapentin dispensed to subject.; Drug
Lead sponsor: Dr. Kirk Brower; Other
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions: NT-I7, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas

Conditions: Ischemia Reperfusion Injury
Interventions: Conjugated Estrogen, Normal saline; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Malignant Digestive System Neoplasm
Interventions: Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride, Electrocardiogram, Fluorouracil, Holter Monitoring, Isosorbide Mononitrate, Medical Device Usage and Evaluation, Placebo Administration, Questionnaire Administration; Procedure · Drug · Device + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Candidemia, Candidiasis, Invasive
Interventions: Fosmanogepix, Caspofungin, Fluconazole, Placebo; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more

Conditions: Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions: Arginine hydrochloride, Sodium Chloride 0.9%; Drug
Lead sponsor: David K Carroll; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
Interventions: Sildenafil, Losartan, Sildenafil and Losartan, Placebo Oral Tablet; Drug
Lead sponsor: Alicia Gerke; Other
Eligibility: 18 Years to 99 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease
Interventions: sepofarsen, Sham; Drug · Other
Lead sponsor: ProQR Therapeutics; Industry
Eligibility: 8 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Immune Surveillance, Stem Cell Surveillance
Interventions: A low dose of seaweed extract, A high dose of seaweed extract, Placebo; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Trauma, Hemorrhage
Interventions: Calcium Gluconate, Vasopressin, saline placebo; Drug
Lead sponsor: Jason Sperry; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 13 more

Conditions: Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions: Sodium Acetate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Kidney Disease, Type 1 Diabetes Mellitus
Interventions: Finerenone, Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 28
States / cities: Surprise, Arizona • Stanford, California • Vallejo, California + 22 more

Conditions: Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss, Weight Loss Trajectory, Weight, Body
Interventions: Semaglutide 2.4mg, Placebo; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Premenstrual Syndrome, Women Health
Interventions: Shatavari Root Extract, Placebo Capsule; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Plantar Fasciitis
Interventions: Duolith SD1, Sham Duolith SD1; Device
Lead sponsor: Storz Medical AG; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 6
States / cities: Palo Alto, California • Hamden, Connecticut • Newtown, Connecticut + 3 more

Conditions: Brain Injuries, Visually Impaired Persons
Interventions: Vision Restoration Therapy, NVT Eye Scanning Therapy, Eccentric Viewing Training, Sham; Other · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 20 Years to 79 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

Psilocybin Therapy in Advanced Cancer

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

Vestibular Balance Therapy Intervention for Children

Decreasing Physician Burnout With Professional Coaching

Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure

Exercise, Milk Thistle, and Lactobacillus to Influence Plasma Bilirubin

Pharmacotherapy and Mechanisms of Sleep Disturbance in Alcohol Dependence

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Intravenous Estrogen in Kidney Transplant Study

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

Rapid Effects on Antioxidant Status, Immune Alertness, and Regenerative Activity

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

Latino Semaglutide Study

Efficacy and Safety of Shatavari Root Extract for Premenstrual Syndrome in Women

Study of Effectiveness and Safety of Extracorporeal Shock Wave Therapy (ESWT) for Treatment of Painful Heel Syndrome

Functional Vision in TBI